Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antihypertensive agent |
| gptkbp:approvedBy |
1960
|
| gptkbp:ATCCode |
C02AB01
|
| gptkbp:brand |
Aldomet
Aldoril |
| gptkbp:CASNumber |
555-30-6
|
| gptkbp:chemicalFormula |
C10H13NO4
|
| gptkbp:contraindication |
MAO inhibitor use
active hepatic disease |
| gptkbp:discoveredBy |
gptkb:Merck_&_Co.
|
| gptkbp:drugClass |
alpha-2 adrenergic agonist
|
| gptkbp:eliminationHalfLife |
1.5–2 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
methyldopa
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
centrally acting alpha-2 adrenergic agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
211.22 g/mol
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
gptkb:depression
gptkb:anemia headache drowsiness dry mouth liver dysfunction |
| gptkbp:usedFor |
treatment of hypertension
|
| gptkbp:usedInPregnancy |
yes
|
| gptkbp:WHOModelListOfEssentialMedicines |
true
|
| gptkbp:bfsParent |
gptkb:autoimmune_hemolytic_anemia
|
| gptkbp:bfsLayer |
6
|